OBJECTIVES: To test whether recently developed methods for comprehensive profiling of the high-density lipoprotein (HDL) glycome combined with the HDL proteome can distinguish individuals with coronary artery disease (CAD) from those without. METHODS: Twenty subjects at risk for CAD, who underwent diagnostic coronary arteriography, were analyzed. Ten subjects had CAD, and ten did not. HDL was extracted from fasting plasma samples by ultracentrifugation, followed by shotgun proteomic, glycomic, and ganglioside analyses using LC-MS. CAD vs non-CAD subjects' data were compared using univariate and multivariate statistics. RESULTS: Principal components analysis showed a clear separation of CAD and non-CAD subjects, confirming that combined HDL proteomic and glycomic profiles distinguished at-risk subjects with atherosclerosis from those without. CAD patients had lower HDL apolipoprotein content (specifically ApoA-I, A-II, and E, p < 0.05), and lower serum amyloid A2 (SAA2, p = 0.020) and SAA4 (p = 0.007) but higher sialylated glycans (p < 0.05). CONCLUSION: Combined proteomic and glycomic profiling of isolated HDL was tested as a novel analytical approach for developing biomarkers of disease. In this pilot study we found that HDL proteome and glycome distinguished between individuals who had CAD from those who did not within a group of individuals equally at risk for heart disease.
OBJECTIVES: To test whether recently developed methods for comprehensive profiling of the high-density lipoprotein (HDL) glycome combined with the HDL proteome can distinguish individuals with coronary artery disease (CAD) from those without. METHODS: Twenty subjects at risk for CAD, who underwent diagnostic coronary arteriography, were analyzed. Ten subjects had CAD, and ten did not. HDL was extracted from fasting plasma samples by ultracentrifugation, followed by shotgun proteomic, glycomic, and ganglioside analyses using LC-MS. CAD vs non-CAD subjects' data were compared using univariate and multivariate statistics. RESULTS: Principal components analysis showed a clear separation of CAD and non-CAD subjects, confirming that combined HDL proteomic and glycomic profiles distinguished at-risk subjects with atherosclerosis from those without. CAD patients had lower HDL apolipoprotein content (specifically ApoA-I, A-II, and E, p < 0.05), and lower serum amyloid A2 (SAA2, p = 0.020) and SAA4 (p = 0.007) but higher sialylated glycans (p < 0.05). CONCLUSION: Combined proteomic and glycomic profiling of isolated HDL was tested as a novel analytical approach for developing biomarkers of disease. In this pilot study we found that HDL proteome and glycome distinguished between individuals who had CAD from those who did not within a group of individuals equally at risk for heart disease.
Authors: Karli R Reiding; L Renee Ruhaak; Hae-Won Uh; Said El Bouhaddani; Erik B van den Akker; Rosina Plomp; Liam A McDonnell; Jeanine J Houwing-Duistermaat; P Eline Slagboom; Marian Beekman; Manfred Wuhrer Journal: Mol Cell Proteomics Date: 2016-12-08 Impact factor: 5.911
Authors: Sridevi Krishnan; Michiko Shimoda; Romina Sacchi; Muchena J Kailemia; Guillaume Luxardi; George A Kaysen; Atul N Parikh; Viviane N Ngassam; Kirsten Johansen; Glenn M Chertow; Barbara Grimes; Jennifer T Smilowitz; Emanual Maverakis; Carlito B Lebrilla; Angela M Zivkovic Journal: Sci Rep Date: 2017-03-13 Impact factor: 4.379
Authors: Tyler Kim; Yixuan Xie; Qiongyu Li; Virginia M Artegoitia; Carlito B Lebrilla; Nancy L Keim; Sean H Adams; Sridevi Krishnan Journal: Eur J Nutr Date: 2021-03-26 Impact factor: 5.614